J-series prostaglandin-ethanolamides as novel therapeutics
Patent Number: US9328060
Executive Summary:
General Description:
Most cancer chemotherapeutic agents kill tumor cells and cause damage to nontumor cells leading to serious and sometimes life threatening adverse effects. The compounds and compositions of the invention can overcome this problem by exploiting biochemical differences between tumor and nontumor cells. Moreover, topical drug application directly to the tumor and/or surrounding area will also aid in decreasing damage to nontumor cells. The compounds and compositions of the invention can also be effective when applied after surgical tumor removal (adjuvant therapy). It can also be useful against multifocal tumors or tumors that cannot be surgically removed due to their location on the skin.
In an aspect of the invention, provided is a compound, 15-deoxy Δ12,14-prostagladin J2-ethanolamide (15-deoxy Δ12,14PGJ2-EA), of formula, and related derivatives and salts
Scientific Progress:
J-series prostaglandin-ethanolamides as novel therapeutics (ref. 1).
Prostaglandin D analogues, process for their preparation and compositions containing them (ref. 2, 3)
Future Directions:
Strengths:
Patent Status:
Publications:
1 Davidson et al. "Eicosapentaenoic acid suppression of systemic inflammatory responses and inverse up-regulation of 15-deoxyDelta12, 14 , Prostaglandin J2 production", British J. Pharmacology 169:1130-1139 (2013).
2. https://patents.google.com/patent/EP0098141A2/en
3. Glass et al. "Misidentification of prostamides as prostaglandins", J. Lipid Research 46:1364-1368 (2005).S. Kim, H. J. Kim and N. L. Jeon, Integr. Biol., 2010, 2, 584-603.
Inventor Bio: Rukiyah T. Van Dross-Anderson
http://www.ecu.edu/cs-dhs/pharmacology/vandross.cfm
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Granted
- Patent Link: https://patents.google.com/patent/US9328060/
- Research Institute: East Carolina University
- Disease Focus: Non-melanoma skin cancer (NMSC) and colorectal cancer
- Basis of Invention: This invention is pharmaceutical composition comprising the compound of formula (I), a pharmaceutical composition comprising anandamide (AEA) and methods of using the same in the treatment of non-melanoma skin cancer (NMSC) and colorectal cancer
- How it works: The present invention relates to novel therapeutics and pharmaceutical compositions including J-series prostaglandin-ethanolamides, and methods of using and administering the same
- Lead Challenge Inventor: Rukiyah T. Van Dross, Daniel A. Ladin, Colin S. Burns, Allison Stokes Danell
- Inventors: Rukiyah T. Van Dross
- Development Stage: In vitro data
- Novelty:
- Therapeutic capable of exploiting biochemical differences between tumor and nontumor cells. Topical drug application directly to the tumor and/or surrounding area will also aid in decreasing damage to nontumor cells
- Clinical Applications:
- Skin, Colorectal cancers
General Description:
Most cancer chemotherapeutic agents kill tumor cells and cause damage to nontumor cells leading to serious and sometimes life threatening adverse effects. The compounds and compositions of the invention can overcome this problem by exploiting biochemical differences between tumor and nontumor cells. Moreover, topical drug application directly to the tumor and/or surrounding area will also aid in decreasing damage to nontumor cells. The compounds and compositions of the invention can also be effective when applied after surgical tumor removal (adjuvant therapy). It can also be useful against multifocal tumors or tumors that cannot be surgically removed due to their location on the skin.
In an aspect of the invention, provided is a compound, 15-deoxy Δ12,14-prostagladin J2-ethanolamide (15-deoxy Δ12,14PGJ2-EA), of formula, and related derivatives and salts
Scientific Progress:
J-series prostaglandin-ethanolamides as novel therapeutics (ref. 1).
Prostaglandin D analogues, process for their preparation and compositions containing them (ref. 2, 3)
Future Directions:
- Development of in vivo/ pre-clinical studies for safety and efficacy in different types of cancers
Strengths:
- AEA induces cell death in diseased, but not healthy cells. AEA-induced ER stress and apoptosis is COX-2 dependent. D- and J-series PGs induce cell death in tumorigenic keratinocytes.
Patent Status:
- Priority date 2013-10-18
- Filing date 2014-10-17
- Publication date 2016-05-03
- Grant date 2016-05-03
Publications:
1 Davidson et al. "Eicosapentaenoic acid suppression of systemic inflammatory responses and inverse up-regulation of 15-deoxyDelta12, 14 , Prostaglandin J2 production", British J. Pharmacology 169:1130-1139 (2013).
2. https://patents.google.com/patent/EP0098141A2/en
3. Glass et al. "Misidentification of prostamides as prostaglandins", J. Lipid Research 46:1364-1368 (2005).S. Kim, H. J. Kim and N. L. Jeon, Integr. Biol., 2010, 2, 584-603.
Inventor Bio: Rukiyah T. Van Dross-Anderson
http://www.ecu.edu/cs-dhs/pharmacology/vandross.cfm